Overview

Trial of LBH589 in Metastatic Thyroid Cancer

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the tumor response rate in patients with metastatic medullary thyroid cancer (MTC) or radioiodine resistant differentiated thyroid cancer (DTC) after receiving treatment with LBH589 20 mg by mouth, three times weekly. Time to progression, overall survival, toxicity, tolerability, and Notch1 protein expression patterns will also be evaluated.

Phase:

Phase 2

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Novartis Pharmaceuticals

Treatments:

Panobinostat